^
Association details:
| Biomarker: | ER positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | ipatasertib (RG7440) (PI3K inhibitor, AKT inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor
Excerpt:
...- Histologically and/or cytologically confirmed ER positive, HER-2 negative breast cancer...
Trial ID:
Source:
Title:
Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression
Excerpt:
...Histological diagnosis of metastatic or inoperable locally advanced ER positive/HER2 negative breast cancer....
Trial ID:
Less C2 evidence
Source:
Title:
395P - Interim analysis (IA) of the giredestrant (G) + ipatasertib (IPAT) arm in MORPHEUS Breast Cancer (BC): A phase I/II study of G treatment (tx) combinations in patients (pts) with oestrogen receptor-positive (ER+), HER2-negative, locally advanced/metastatic BC (LA/mBC)
Published date:
10/16/2023
Excerpt:
In the overall population the ORR was 0%/17% (n = 4) and stable disease (SD) was 63% (n = 5)/52% (n = 12) in the G and G + IPAT arms, respectively….Encouraging activity was seen with G + IPAT in pts with disease progression on 1–2 lines of ET (including a CDK4/6i)...G + IPAT was well tolerated, with no unexpected safety signals.
Secondary therapy:
GDC-9545
Trial ID:
